hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06377813 id: REC/RCR& AHS/23/01100/Maryam briefTitle: Combined Mode-Kinetic Chain Exercise With and Without Core Stability Exercises on Patients With Knee Osteoarthritis overallStatus: RECRUITING date: 2023-11-20 date: 2024-06-01 date: 2024-06-01 date: 2024-04-22 date: 2024-04-22 name: Riphah International University class: OTHER briefSummary: The goal of this \[type of study: Randomized control trial\] is to \[ see the effects of Combined Mode Kinetic Chain Exercises along with or without core stability exercises on pain, range of motion and disability \] in \[ in patients with Knee Osteoarthritis\].The main question it aims to answer is:
Wether core stability exercises is effective if performed along with Combined chain kinetic exercises to improves the condition of Knee Osteoarthritis? Group A will receive Core Stability Exercises along with Combined Chain Kinetic Exercises and Group B will receive combined Chain Kinetic Exercises. conditions: Knee Osteoarthritis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Assignment primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 48 type: ESTIMATED name: Mode-Kinetic Chain Exercise With Core Stability Exercises name: Mode-Kinetic Chain Exercise measure: Numeric pain rating scale measure: Kellgren and Lawrence system for classification of Osteoarthritis measure: Knee Injury and Osteoarthritic outcome score (KOOS) measure: Goniometer sex: ALL minimumAge: 40 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Riphah International University status: RECRUITING city: Lahore state: Punjab zip: 54000 country: Pakistan name: Muhammad Sanaullah, MS role: CONTACT phone: 03224819253 email: muhammad.sanaullah@riphah.edu.pk name: Maryam Maqsood, DPT role: CONTACT phone: 03314815652 email: mail.maryam70@gmail.com lat: 31.558 lon: 74.35071 hasResults: False
nctId: NCT06377800 id: REC 01801 Kainat Fatima briefTitle: Effects Of Navicular Mobilization In Patients With Planter Fasciitis overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-06 date: 2024-07 date: 2024-04-22 date: 2024-04-22 name: Riphah International University class: OTHER briefSummary: The significance of studying the effects of navicular mobilization in patients suffering from plantar fasciitis lies in its potential to provide valuable insights into non-invasive treatment approaches for a common and debilitating foot condition such as flat foot. Understanding how this therapy impacts navicular height, pain and disability of the foot can lead to improved clinical outcomes and a better understanding of the biomechanical factors contributing to plantar fasciitis. Ultimately, this research may help refine treatment strategies and enhance the quality of life for individuals suffering from this condition conditions: Plantar Fascitis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 32 type: ESTIMATED name: navicular mobilization along conventional therapy. name: conventional therapy measure: Numeric Pain Rating Scale measure: (Foot Function Index) measure: Navicular drop test measure: Foot print analysis sex: ALL minimumAge: 18 Years maximumAge: 30 Years stdAges: ADULT facility: DHQ Hospital city: Faisalābad state: Punjab country: Pakistan name: Maria Khalid, MSOMPT role: CONTACT phone: 03315369768 email: maria.khalid@riphah.edu.pk name: Kainat Fatima, MSOMPT* role: CONTACT name: Kainat Fatima, MSOMPT* role: PRINCIPAL_INVESTIGATOR lat: 31.41554 lon: 73.08969 hasResults: False
nctId: NCT06377787 id: REC 01732 Aneeqa Zaheer briefTitle: Effects of ELDOA in Patients With Cervicogenic Headache overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-06 date: 2024-07 date: 2024-04-22 date: 2024-04-22 name: Riphah International University class: OTHER briefSummary: The aim of our study is to determine the effect of ELDOA in relieving pain, improving ROM and functional disability in patients with cervicogenic headache. This study will add to the growing body of knowledge that if this technique yields comparable outcomes, it would be the alternative therapy. Moreover, it would add to the society as no literature is available on the effect of ELDOA technique in the management of Cervicogenic headache. conditions: Cervicogenic Headache studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 24 type: ESTIMATED name: ELDOA and conventional therapy name: conventional therapy measure: (Numeric Pain Rating Scale). measure: NDI (U) (Neck Disability Index) measure: Inclinometer sex: ALL minimumAge: 30 Years maximumAge: 45 Years stdAges: ADULT facility: Alkhidmat Raazi Hospital CBR Town city: Islamabad state: Punjab zip: 46000 country: Pakistan name: Maria Khalid, MSOMPT role: CONTACT phone: 03315369768 email: maria.khalid@riphah.edu.pk name: Aneeqa Zaheer, MSOMPT* role: CONTACT name: Aneeqa Zaheer, MSOMPT* role: PRINCIPAL_INVESTIGATOR lat: 33.72148 lon: 73.04329 hasResults: False
nctId: NCT06377774 id: NFEC-2024-096 briefTitle: To Optimize Therapeutic Procedures of DPMAS in ACLF Patients: a Prospective, Sigle Arm and Multicenter Study overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-03-30 date: 2026-02-01 date: 2024-04-22 date: 2024-04-22 name: Nanfang Hospital, Southern Medical University class: OTHER briefSummary: Acute-on-chronic liver failure (ACLF) is a life-threaten syndrome carrying high-short-term mortality raging 40% to 60% within 90 days in patients with chronic liver disease. Double plasma molecular adsorption system (DPMAS) is one of the available artificial liver support systems, which combines plasma filtration and two specific adsorption membranes dedicating to remove bilirubin and the middle molecular toxins respectively. The efficiency of DMPAS treatment in liver failure patients remains controversial. Previous study indicate that liver failure patients with DPMAS therapy improve the short-term mortality and prevent the diseases progression within 28 days (PADSTONE Study). Thus, this single-arm, multicenter and prospective study is to further validate and optimize the therapeutic procedures of DPMAS therapy in ACLF patients. conditions: Acute-On-Chronic Liver Failure studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 2000 type: ESTIMATED name: No intervention in this study measure: 28-day transplantation-free mortality measure: The disease progression rate measure: the 90-day transplantation-free mortality measure: the disease progression sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06377761 id: BF-2022-121 briefTitle: Study on Heart Failure With Preserved Ejection Fraction With Qishen Granules overallStatus: RECRUITING date: 2023-05-01 date: 2024-12-31 date: 2025-12-31 date: 2024-04-22 date: 2024-04-22 name: Guangdong Provincial Hospital of Traditional Chinese Medicine class: OTHER briefSummary: With the cardiopulmonary exercise testing as the primary outcome, the study aims to evaluate the efficacy of Qishen Granules on cardiac function, quality of life and biomarker level of patients with heart failure with preserved ejection fraction (HFpEF), which will provide evidence for the treatment of HFpEF with traditional Chinese medicine. conditions: Heart Failure With Preserved Ejection Fraction studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Random parallel grouping primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: Qishen Granules name: Placebo measure: Changes in peak oxygen uptake within the average minute (PeakVO2) compared to baseline on day 90 measure: Changes in Mitral valve diastolic blood flow velocity (E) and Mitral annulus lateral and septal motion velocity (e') compared to baseline on day 90 measure: Changes in E/e' ratio compared to baseline on day 90 measure: Changes in Left Atrial Volume index (LAVI) compared to baseline on day 90 measure: Changes in Left ventricular mass index (LVMI) compared to baseline on day 90 measure: Changes in Score of Kansas City Cardiomyopathy Questionnaire (KCCQ) compared to baseline on day 90 measure: Changes in blood N terminal pro B type natriuretic peptide(NT-proBNP) compared to baseline on day 90 measure: Changes in blood Growth STimulation expressed gene 2(ST2) compared to baseline on day 90 measure: Changes in blood urea compared to baseline on day 90 measure: Changes in blood creatinine compared to baseline on day 90 measure: Changes in Aspartate aminotransferase(AST) compared to baseline on day 90 measure: Changes in Alanine aminotransferase(ALT) compared to baseline on day 90 measure: Number of participants with treatment-related adverse events sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Guangdong Provincial Hospital of Chinese Medicine status: RECRUITING city: Guangzhou state: Guangdong zip: 510120 country: China name: Lei Wang, M.D role: CONTACT phone: 8620-81887233-32801 email: Dr.wanglei@139.com lat: 23.11667 lon: 113.25 facility: WangLei status: RECRUITING city: Guangzhou state: Guangdong zip: 510120 country: China name: Lei Wang, doctorate role: CONTACT phone: +8613724078381 email: Dr.wanglei@139.com name: Shuai Mao, doctorate role: CONTACT phone: 86-20-81887233-32801 email: maoshuaitcm@163.com lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06377748 id: 2023/02 briefTitle: The Effect of Facilitated-tucking and ShotBlocker on Pain Caused by Vaccination in Healthy Infants overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-07-30 date: 2024-07-30 date: 2024-04-22 date: 2024-04-22 name: Istanbul Medeniyet University class: OTHER briefSummary: This study will be investigated the effects of facilitated tucking, ShotBlocker and combined facilitated tucking and ShotBlocker methods on procedural pain, crying time and duration of the procedure during Hepatitis B vaccine administration in healthy term infants. conditions: Procedural Pain conditions: Pain, Acute conditions: Nursing Caries studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Participants will be assigned to experimental and control groups using block randomization method. Birth weight (2500-3000 g, 3001-3500 g, 3501 g and above), gender (male and female) and mode of delivery (vaginal and cesarean section) variables will be used for block randomization. primaryPurpose: SUPPORTIVE_CARE masking: DOUBLE maskingDescription: Using the block randomization technique, participants will be divided into 4 groups. A web-based randomization list creation tool will be used to create the blocked randomization list. Control and intervention groups will be coded as A, B, C and D using the sealed envelope method. Randomization information will be kept from the researcher involved in data collection until data collection begins. The researcher will learn which group each baby is in just before the application (researcher blinding).
Research data will be entered into the computer database by coding the group name as A, B, C and D, and statistical analysis will be performed using this coding (statistician blinding). whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 144 type: ESTIMATED name: Facilitated tucking position name: ShotBlocker name: Combined facilitated tucking and ShotBlocker measure: Neonatal Infant Pain Scale measure: Crying time during the procedure measure: Procedure time sex: ALL minimumAge: 38 Weeks maximumAge: 42 Weeks stdAges: CHILD facility: Istanbul Medeniyet University city: Istanbul state: Kadıköy zip: 34720 country: Turkey name: Aynur Aytekin Özdemir, PhD role: CONTACT lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06377735 id: CHEST-001 briefTitle: BAI-BACE for Advanced Lung Squamous Cell Carcinoma overallStatus: RECRUITING date: 2024-05-01 date: 2025-12-30 date: 2026-12-30 date: 2024-04-22 date: 2024-04-24 name: Sun Yat-sen University class: OTHER briefSummary: Bronchial arterial infusion plus bronchial arterial chemoembolization (BAI-BACE) has been reported as non-first-line therapy to treat lung cancer in many hospitals in China. BAI, which uses chemotherapeutic drugs directly injected into the tumor and achieved a high concentration in a short time to kill the tumor. Then BACE could seal off the tumor vessels. In this study, we aim to describe the efficacy and safety of BAI-BACE as non-first-line for advanced lung squamous cell carcinoma. conditions: Squamous Cell Carcinoma studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Bronchial arterial infusion, bronchial arterial chemoembolization (BACE-BAI) procedure was performed as follows: Bronchial arteriography was performed to find tumor-feeding artery. After the catheter had been inserted into the tumor-feeding artery, paclitaxel (300 mg) was infused slowly at least 30 min. BAI (bronchial arterial infusion) chemotherapy was followed by BACE (Drug-eluting beads bronchial arterial chemoembolization); the CalliSpheres loaded with cis-platinum (30 mg) were infused into the tumor-feeding arteries until stasis or near-stasis of blood flow in the vessel was observed. primaryPurpose: TREATMENT masking: NONE count: 85 type: ESTIMATED name: BAI-BACE measure: Progression-Free-Survival (PFS) measure: Overall survival (OS) measure: Objective response rate (ORR) measure: Adverse events sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Chinese PLA General hospital status: RECRUITING city: Beijing state: Beijing zip: 100853 country: China name: Qunfang Zhou, MD role: CONTACT phone: 8619868000115 email: zhouqun988509@163.com name: Feng Duan, MD role: CONTACT phone: 8613910984586 email: duanfeng@vip.sina.com lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06377722 id: CABOPRE briefTitle: Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer overallStatus: TERMINATED date: 2018-11-01 date: 2022-08-09 date: 2022-08-09 date: 2024-04-22 date: 2024-04-26 name: Fundacion Oncosur class: NETWORK briefSummary: Phase II, multicenter, national, uncontrolled, multicenter, uncontrolled, phase II clinical trial for the evaluation of cabozantinib treatment prior to cytoreductive nephrectomy in patients with advanced or metastatic renal cell cancer candidates for primary tumor cytoreductive nephrectomy (NC). conditions: Renal Cell Carcinoma Metastatic conditions: Renal Cell Carcinoma Stage IV conditions: Renal Cell Carcinoma Stage III studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 18 type: ACTUAL name: Cabozantinib measure: Radiological response rate prior to cytoreductive nephrectomy sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hospital Universitario Central de Asturias city: Oviedo state: Asturias country: Spain lat: 43.36029 lon: -5.84476 facility: Institut Català d'Oncologia. Idibell city: L'Hospitalet de Llobregat state: Barcelona country: Spain lat: 41.35967 lon: 2.10028 facility: Hospital Universitario de Valdecilla city: Santander state: Cantabria country: Spain lat: 43.46472 lon: -3.80444 facility: Hospital Univeristario 12 de Octubre city: Madrid zip: 28041 country: Spain lat: 40.4165 lon: -3.70256 facility: Centro Oncológico Clara Campal - HM CIOCC city: Madrid country: Spain lat: 40.4165 lon: -3.70256 facility: Hospital Universitario La Paz city: Madrid country: Spain lat: 40.4165 lon: -3.70256 facility: Hospital Universitario Ramón y Cajal city: Madrid country: Spain lat: 40.4165 lon: -3.70256 facility: Hospital Universitario Severo Ochoa city: Madrid country: Spain lat: 40.4165 lon: -3.70256 hasResults: False
nctId: NCT06377709 id: 24CP001 briefTitle: A Mixed-methods Acceptability Study of ProACTive™ to Help Burns Patients Adjust to Changes to Appearance overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2024-12 date: 2024-12 date: 2024-04-22 date: 2024-04-24 name: Nottingham University Hospitals NHS Trust class: OTHER briefSummary: This mixed-methods acceptability study aims to investigate whether an early acceptance and commitment therapy (ACT) based intervention called ProACTive™, aimed at supporting burns patients' adjustment to a changed appearance and preventing distress, is acceptable. This will be measured by descriptive data, questionnaire data and semi-structured interviews.
Preliminary data on the potential clinical effectiveness of the intervention will also be gathered. This will be measured by scores on standardised questionnaires. conditions: Burn Injuries conditions: Burns conditions: Emotional Distress conditions: Adjustment studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 15 type: ESTIMATED name: ProACTive™ measure: Body Esteem Scale for Adolescents and Adults - Appearance subscale (BESAA-A) measure: Positive and Negative Affect Schedule (PANAS-GEN) measure: Comprehensive assessment of Acceptance and Commitment Therapy processes (CompACT) measure: Self-Compassion Scale - Short Form (SCS-SF) measure: Helpful Aspects of Therapy Form (HAT) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06377696 id: MC230713 id: NCI-2024-02980 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) id: MC230713 type: OTHER domain: Mayo Clinic in Rochester id: 23-005512 type: OTHER domain: Mayo Clinic Institutional Review Board briefTitle: Remote Cognitive Assessment Battery and Wearable Device Monitoring Platform While Assessing the Impact of Metformin in Patients With History of Cranial Radiation Therapy overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2027-04-30 date: 2027-04-30 date: 2024-04-22 date: 2024-04-26 name: Mayo Clinic class: OTHER briefSummary: This phase III trial evaluates whether patient care can be done remotely for patients having cranial (skull) radiation or who have previously had cranial radiation. In addition, this trial compares study outcomes between patients who get metformin and those who do not. Cranial radiation, an essential component of brain tumor treatment, can result in significant negative effects on cognitive (the ability to clearly think, learn, and remember) function. Wearable devices have been used in the field of neurology for seizure detection and assessment of patients with movement disorders. Wearable device technology has also been implemented for remote monitoring of cancer patients and for cancer clinical trials. Metformin is the active ingredient in a drug used to treat type 2 diabetes mellitus (a condition in which the body cannot control the level of sugar in the blood). It is also being studied in the treatment of cancer. Use of metformin may reduce risk of cognitive decline following radiation therapy within the skull (intracranial). These effects may be further strengthen by addition of device-based physical activity promotion. Mayo Test Drive is a web-based platform for remote self-administered cognitive assessment. Using Mayo Test Drive may help determine whether patient care can be done remotely, while simultaneously evaluating benefits of health promotion through use of a wearable watch device and metformin in preventing radiation-related cognitive decline. conditions: Malignant Brain Neoplasm studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 100 type: ESTIMATED name: Best Practice name: Medical Device Usage and Evaluation name: Metformin name: Neurocognitive Assessment name: Questionnaire Administration measure: Compliance of patients who complete the testing schedule for the cognitive assessments (Feasibility) measure: Overall completion rates and compliance (Feasibility) measure: Overall satisfaction measure: Adherence (Feasibility) measure: Neurocognitive scores measure: Incidence of adverse events (AEs) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mayo Clinic in Rochester city: Rochester state: Minnesota zip: 55905 country: United States name: Clinical Trials Referral Office role: CONTACT phone: 855-776-0015 email: mayocliniccancerstudies@mayo.edu name: Ugur T. Sener, M.D. role: PRINCIPAL_INVESTIGATOR lat: 44.02163 lon: -92.4699 hasResults: False
nctId: NCT06377683 id: XMYY-2023KY122 briefTitle: Clinical Evaluation of 177Lu-DansyI-PSMA (LNC1011) in Patients With Metastatic Castration-Resistant Prostate Cancer overallStatus: RECRUITING date: 2024-04-05 date: 2025-12-30 date: 2026-12-30 date: 2024-04-22 date: 2024-04-22 name: The First Affiliated Hospital of Xiamen University class: OTHER briefSummary: Ten to 20% of patients with prostate cancer (PC) experience progression in their disease, even after undergoing pharmaceutical or surgical castration, leading to metastatic CRPC (mCRPC). Prostate-specific membrane antigen (PSMA) is a membrane-bound glycoprotein mostly specific to the prostate. While PSMA is expressed at low levels in normal prostate, this expression increased by 100-1000-fold in PC, which makes it a favorable target for therapy. This study was designed to evaluate the safety, tolerability, and maximum tolerated dose of a long-lasting radiolabeled ligand 177Lu-Dansyl-PSMA in mCRPC patients. conditions: Metastatic Castration-resistant Prostate Cancer, mCRPC studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: classic 3+3 dose escalation primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: 177Lu-Dansyl-PSMA radioligand therapy measure: Incidence of treatment-related adverse events (safety and tolerability) measure: To determine the maximum tolerated dose (MTD) measure: Dosimetry sex: MALE minimumAge: 21 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The First Affiliated Hospital of Xiamen University status: RECRUITING city: Xiamen state: Fujian zip: 361003 country: China name: Haojun Chen, MD, PhD role: CONTACT phone: +8618659285282 email: leochen0821@foxmail.com name: Hao Fu, MD, PhD role: CONTACT phone: +8615959230059 email: fuhaonuclear@163.com name: Haojun Chen, MD, PhD role: PRINCIPAL_INVESTIGATOR name: Hao Fu, MD, PhD role: SUB_INVESTIGATOR lat: 24.47979 lon: 118.08187 hasResults: False
nctId: NCT06377670 id: 38RC24.0012 briefTitle: Study of Functional and Aesthetic Outcomes After Wassel IV Thumb Duplication Surgery in Pediatric Population, With a Follow-up of at Least One Year overallStatus: NOT_YET_RECRUITING date: 2024-04-25 date: 2024-05-06 date: 2024-05-15 date: 2024-04-22 date: 2024-04-22 name: University Hospital, Grenoble class: OTHER briefSummary: The purpose of this study is to evaluate the functional and aesthetic outcomes in children with Wassel IV thumb duplication conditions: Wassel IV Thumb Duplication studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: RETROSPECTIVE count: 30 type: ESTIMATED name: Wassel IV Thumb Duplication Surgery measure: Functional and Aesthetic Outcomes measure: Comparison of Surgical Techniques measure: Efficacy of Skin Flap Types measure: Immobilization Method Analysis measure: Preoperative Angle Decision Model sex: ALL minimumAge: 1 Year maximumAge: 18 Years stdAges: CHILD stdAges: ADULT hasResults: False